InspireMD, Inc.NSPR
Price (close)
$0.70
Market cap
$32.8M
P/E
—
Revenue (TTM)
$10.8M
Net income
-$52.5M
Dividend yield
—
1-year total return
-70.5%
Net margin
-484.1%
Revenue growth
53.4%
Debt / equity
—
What InspireMD, Inc. does.
are a medical device company specializing in the development and commercialization of products for the treatment of carotid artery disease
and other vascular conditions. Our portfolio includes two commercial products based on our proprietary CGuard carotid stent technology,
designed to provide market-leading embolic protection during and after stenting procedures. A stent is an expandable scaffold-like metallic
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $2.5M | $4.5M | $5.2M | $6.2M | $7.0M | $9.0M |
| Net income | -$10.5M | -$14.9M | -$18.5M | -$19.9M | -$32.0M | -$48.8M |
| Free cash flow | -$9.2M | -$13.6M | -$16.0M | -$16.8M | -$23.3M | -$36.8M |
More on NSPR.
- InspireMD, Inc. summary
- InspireMD, Inc. financial statements
- InspireMD, Inc. key metrics
- InspireMD, Inc. health scores and style box
- InspireMD, Inc. earnings
- InspireMD, Inc. dividends
- InspireMD, Inc. valuation
- InspireMD, Inc. ownership and insiders
- InspireMD, Inc. peers
Figures from InspireMD, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.